Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream

Seiichi Yamano, Bruce J. Baum, Li Yun Huang, Chuantian Ding, John A. Chiorini, Corinne M. Goldsmith, Robert B. Wellner, Basil Golding, Robert M. Kotin, Dorothy E. Scott

Research output: Contribution to journalArticle

Abstract

We have constructed a recombinant adeno-associated virus serotype 2 vector encoding human interleukin 10 (rAAVhIL10). IL-10 is a potent antiinflammatory/immune cytokine, which has received growing attention for its therapeutic potential. Human IL-10 (hIL-10) production was virus dose dependent after in vitro infection of HSG cells, a human submandibular gland cell line. The vector-derived hIL-10 produced was biologically active, as the medium from rAAVhIL10-infected HSG cells caused a dose-dependent blockade of IL-12 secretion from spleen cells of IL-10 knockout mice challenged with heat-killed Brucella abortus. Administration of rAAVhIL10 (1010 genomes per gland) to both mouse submandibular glands led to hIL-10 secretion into the bloodstream (∼1-5 pg/ml), that is, in an endocrine manner, which was stable for ∼ 2 months. Salivary gland administration of rAAVhIL10 under experimental conditions was more efficacious than intravenous administration (∼0.5-0.7 pg/ml). Also, hIL-10 was readily secreted in vitro from organ cultures of minced submandibular glands infected with rAAVhIL10, 6 or 8 weeks earlier. Consistent with these results, hIL-10 mRNA was detected by reverse transcription-polymerase chain reaction in submandibular glands of mice infected with rAAVhIL10 but not from control mice. At these doses, little to no hIL-10 was detected in mouse saliva. Using a rAAV serotype 2 vector encoding β-galactosidase, we observed that the primary parenchymal target cells were ductal. These findings represent the first report of rAAV use to target exocrine glands for systemic secretion of a therapeutic protein, and support the notion that rAAV serotype 2 vectors may be useful in salivary glands for local (periglandular) and systemic gene-based protein therapeutics.

Original languageEnglish (US)
Pages (from-to)287-298
Number of pages12
JournalHuman Gene Therapy
Volume13
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Dependovirus
Salivary Glands
Interleukin-10
Submandibular Gland
Serogroup
Galactosidases
Exocrine Glands
Brucella abortus
Organ Culture Techniques
Interleukin-12
Interleukin-8
Saliva
Knockout Mice
Intravenous Administration
Reverse Transcription

ASJC Scopus subject areas

  • Genetics

Cite this

Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream. / Yamano, Seiichi; Baum, Bruce J.; Huang, Li Yun; Ding, Chuantian; Chiorini, John A.; Goldsmith, Corinne M.; Wellner, Robert B.; Golding, Basil; Kotin, Robert M.; Scott, Dorothy E.

In: Human Gene Therapy, Vol. 13, No. 2, 2002, p. 287-298.

Research output: Contribution to journalArticle

Yamano, S, Baum, BJ, Huang, LY, Ding, C, Chiorini, JA, Goldsmith, CM, Wellner, RB, Golding, B, Kotin, RM & Scott, DE 2002, 'Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream', Human Gene Therapy, vol. 13, no. 2, pp. 287-298. https://doi.org/10.1089/10430340252769806
Yamano, Seiichi ; Baum, Bruce J. ; Huang, Li Yun ; Ding, Chuantian ; Chiorini, John A. ; Goldsmith, Corinne M. ; Wellner, Robert B. ; Golding, Basil ; Kotin, Robert M. ; Scott, Dorothy E. / Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream. In: Human Gene Therapy. 2002 ; Vol. 13, No. 2. pp. 287-298.
@article{24da21650c7243de8a573dcec554f9cc,
title = "Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream",
abstract = "We have constructed a recombinant adeno-associated virus serotype 2 vector encoding human interleukin 10 (rAAVhIL10). IL-10 is a potent antiinflammatory/immune cytokine, which has received growing attention for its therapeutic potential. Human IL-10 (hIL-10) production was virus dose dependent after in vitro infection of HSG cells, a human submandibular gland cell line. The vector-derived hIL-10 produced was biologically active, as the medium from rAAVhIL10-infected HSG cells caused a dose-dependent blockade of IL-12 secretion from spleen cells of IL-10 knockout mice challenged with heat-killed Brucella abortus. Administration of rAAVhIL10 (1010 genomes per gland) to both mouse submandibular glands led to hIL-10 secretion into the bloodstream (∼1-5 pg/ml), that is, in an endocrine manner, which was stable for ∼ 2 months. Salivary gland administration of rAAVhIL10 under experimental conditions was more efficacious than intravenous administration (∼0.5-0.7 pg/ml). Also, hIL-10 was readily secreted in vitro from organ cultures of minced submandibular glands infected with rAAVhIL10, 6 or 8 weeks earlier. Consistent with these results, hIL-10 mRNA was detected by reverse transcription-polymerase chain reaction in submandibular glands of mice infected with rAAVhIL10 but not from control mice. At these doses, little to no hIL-10 was detected in mouse saliva. Using a rAAV serotype 2 vector encoding β-galactosidase, we observed that the primary parenchymal target cells were ductal. These findings represent the first report of rAAV use to target exocrine glands for systemic secretion of a therapeutic protein, and support the notion that rAAV serotype 2 vectors may be useful in salivary glands for local (periglandular) and systemic gene-based protein therapeutics.",
author = "Seiichi Yamano and Baum, {Bruce J.} and Huang, {Li Yun} and Chuantian Ding and Chiorini, {John A.} and Goldsmith, {Corinne M.} and Wellner, {Robert B.} and Basil Golding and Kotin, {Robert M.} and Scott, {Dorothy E.}",
year = "2002",
doi = "10.1089/10430340252769806",
language = "English (US)",
volume = "13",
pages = "287--298",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream

AU - Yamano, Seiichi

AU - Baum, Bruce J.

AU - Huang, Li Yun

AU - Ding, Chuantian

AU - Chiorini, John A.

AU - Goldsmith, Corinne M.

AU - Wellner, Robert B.

AU - Golding, Basil

AU - Kotin, Robert M.

AU - Scott, Dorothy E.

PY - 2002

Y1 - 2002

N2 - We have constructed a recombinant adeno-associated virus serotype 2 vector encoding human interleukin 10 (rAAVhIL10). IL-10 is a potent antiinflammatory/immune cytokine, which has received growing attention for its therapeutic potential. Human IL-10 (hIL-10) production was virus dose dependent after in vitro infection of HSG cells, a human submandibular gland cell line. The vector-derived hIL-10 produced was biologically active, as the medium from rAAVhIL10-infected HSG cells caused a dose-dependent blockade of IL-12 secretion from spleen cells of IL-10 knockout mice challenged with heat-killed Brucella abortus. Administration of rAAVhIL10 (1010 genomes per gland) to both mouse submandibular glands led to hIL-10 secretion into the bloodstream (∼1-5 pg/ml), that is, in an endocrine manner, which was stable for ∼ 2 months. Salivary gland administration of rAAVhIL10 under experimental conditions was more efficacious than intravenous administration (∼0.5-0.7 pg/ml). Also, hIL-10 was readily secreted in vitro from organ cultures of minced submandibular glands infected with rAAVhIL10, 6 or 8 weeks earlier. Consistent with these results, hIL-10 mRNA was detected by reverse transcription-polymerase chain reaction in submandibular glands of mice infected with rAAVhIL10 but not from control mice. At these doses, little to no hIL-10 was detected in mouse saliva. Using a rAAV serotype 2 vector encoding β-galactosidase, we observed that the primary parenchymal target cells were ductal. These findings represent the first report of rAAV use to target exocrine glands for systemic secretion of a therapeutic protein, and support the notion that rAAV serotype 2 vectors may be useful in salivary glands for local (periglandular) and systemic gene-based protein therapeutics.

AB - We have constructed a recombinant adeno-associated virus serotype 2 vector encoding human interleukin 10 (rAAVhIL10). IL-10 is a potent antiinflammatory/immune cytokine, which has received growing attention for its therapeutic potential. Human IL-10 (hIL-10) production was virus dose dependent after in vitro infection of HSG cells, a human submandibular gland cell line. The vector-derived hIL-10 produced was biologically active, as the medium from rAAVhIL10-infected HSG cells caused a dose-dependent blockade of IL-12 secretion from spleen cells of IL-10 knockout mice challenged with heat-killed Brucella abortus. Administration of rAAVhIL10 (1010 genomes per gland) to both mouse submandibular glands led to hIL-10 secretion into the bloodstream (∼1-5 pg/ml), that is, in an endocrine manner, which was stable for ∼ 2 months. Salivary gland administration of rAAVhIL10 under experimental conditions was more efficacious than intravenous administration (∼0.5-0.7 pg/ml). Also, hIL-10 was readily secreted in vitro from organ cultures of minced submandibular glands infected with rAAVhIL10, 6 or 8 weeks earlier. Consistent with these results, hIL-10 mRNA was detected by reverse transcription-polymerase chain reaction in submandibular glands of mice infected with rAAVhIL10 but not from control mice. At these doses, little to no hIL-10 was detected in mouse saliva. Using a rAAV serotype 2 vector encoding β-galactosidase, we observed that the primary parenchymal target cells were ductal. These findings represent the first report of rAAV use to target exocrine glands for systemic secretion of a therapeutic protein, and support the notion that rAAV serotype 2 vectors may be useful in salivary glands for local (periglandular) and systemic gene-based protein therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=0036168955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036168955&partnerID=8YFLogxK

U2 - 10.1089/10430340252769806

DO - 10.1089/10430340252769806

M3 - Article

C2 - 11812284

AN - SCOPUS:0036168955

VL - 13

SP - 287

EP - 298

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -